Shinya Satoh, Kyoko Mori, Daichi Onomura, Youki Ueda, Hiromichi Dansako, Masao Honda, Shuichi Kaneko, Masanori Ikeda, Nobuyuki Kato – 13 July 2017 – Ribavirin (RBV) has been widely used as an antiviral reagent, specifically for patients with chronic hepatitis C. We previously demonstrated that adenosine kinase, which monophosphorylates RBV into the metabolically active form, is a key determinant for RBV sensitivity against hepatitis C virus RNA replication. However, the precise mechanism of RBV action and whether RBV affects cellular metabolism remain unclear.

Carmen Cepeda‐Franco, Luis Miguel Marín‐Gómez, Carmen Bernal‐Bellido, Gonzalo Suárez‐Artacho, Jose María Álamo‐Martínez, Francisco Javier Padillo‐Ruiz, Miguel Ángel Gómez‐Bravo – 12 July 2017

Salvador Augustin, Mònica Pons, James B. Maurice, Christophe Bureau, Horia Stefanescu, Michel Ney, Hélène Blasco, Bogdan Procopet, Emmanuel Tsochatzis, Rachel H. Westbrook, Jaime Bosch, Annalisa Berzigotti, Juan G. Abraldes, Joan Genescà – 11 July 2017 – Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening endoscopy with a platelet count >150 × 109 cells/L and a liver stiffness measurement (LSM) <20 kPa (Baveno VI criteria). However, the total number of avoided endoscopies using this rule is relatively low.

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

Karuna Rasineni, Terrence M. Donohue, Paul G. Thomes, Li Yang, Dean J. Tuma, Mark A. McNiven, Carol A. Casey – 10 July 2017 – Lipid droplets (LDs), the organelles central to alcoholic steatosis, are broken down by lipophagy, a specialized form of autophagy. Here, we hypothesize that ethanol administration retards lipophagy by down‐regulating dynamin 2 (Dyn2), a protein that facilitates lysosome re‐formation, contributing to hepatocellular steatosis. Primary hepatocytes were isolated from male Wistar rats fed Lieber–DeCarli control or ethanol (EtOH) liquid diets for 6‐8 weeks.

Shih‐Ho Wang, Poh‐Yen Loh, Ting‐Lung Lin, Li‐Man Lin, Wei‐Feng Li, Yu‐Hung Lin, Chih‐Che Lin, Chao‐Long Chen – 10 July 2017 – De novo hepatitis B virus (DNHB) infections may occur in recipients who do not receive prophylaxis after liver transplantation (LT) with antibody to hepatitis B core antigen (anti‐HBc)–positive donor grafts. Active immunization has been shown to prevent DNHB in pediatric recipients. Our aim is to investigate the efficacy of HBV vaccination for preventing DNHB in adult living donor liver transplantation (LDLT).

Elsa Solà, Pere Ginès – 8 July 2017 – Liver Transplantation 23 1318–1324 2017 AASLD.

Jody C. Olson, Constantine J. Karvellas – 8 July 2017 – Patients with cirrhosis who are awaiting liver transplantation (LT) are at high risk for developing critical illnesses. Current liver allocation policies that dictate a “sickest first” approach coupled with a mismatch between need and availability of organs result in longer wait times, and thus, patients are becoming increasingly ill while awaiting organ transplantation.

David Wyles, Heiner Wedemeyer, Ziv Ben‐Ari, Edward J. Gane, Jesper Bach Hansen, Ira M. Jacobson, Alex L. Laursen, Annie Luetkemeyer, Ronald Nahass, Stephen Pianko, Stefan Zeuzem, Patricia Jumes, Hsueh‐Cheng Huang, Joan Butterton, Michael Robertson, Janice Wahl, Eliav Barr, Hee‐Koung Joeng, Elizabeth Martin, Lawrence Serfaty, for the C‐CREST Part C and C‐SURGE Investigators – 7 July 2017 – People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population.